Sanofi (SNY) Financials
PeriodQ2 FY2026
Published
Sanofi reported net sales of $13.49 billion for Q2 FY2026, the quarter ended June 30, 2026, up 19.0% from a year earlier in US dollar terms, with its largest medicine, Dupixent, contributing $5.99 billion. Net income attributable to Sanofi shareholders was $398.91 million, down 91.1%, and basic earnings were $0.17 per ADS against $1.84, mainly because the quarter carried an impairment writing off the drug candidate amlitelimab while the year-earlier quarter included the gain on the sale of the Opella consumer health business. On Sanofi's non-IFRS business basis, which excludes those items, earnings were $1.22 per ADS, up 34.8% in US dollar terms.
| Metric | Amount | vs. year ago |
|---|---|---|
| Net sales | $13,487,314,574 | up 19.0% |
| Net income | $398,909,106 | down 91.1% |
| Basic EPS per ADS | $0.17 | down 90.8% |
| Business EPS per ADS | $1.22 | up 34.8% |
| Dupixent sales | $5,994,103,588 |
Company details
| Name | Sanofi |
|---|---|
| Ticker | SNY |
| CIK | 0001121404 |
| Exchange | Nasdaq |
| State | France |
| Incorporation | France |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 6-K, accession 0001628280-26-050803 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 6-K, due (projected 2026-10-23) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included, plus a figure_sources block linking each figure the filing tags to the line that prints it.
- 20-F and 6-K summaryPage Qualitative synthesis of the latest 20-F + 6-K: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 6-K filings and eventsPage Digest of material 6-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Sanofi Q2 FY2026
How much revenue did Sanofi make in Q2 FY2026?
Sanofi reported net sales of $13.49 billion for Q2 FY2026, the quarter ended June 30, 2026. That is up 19.0% in US dollar terms from $11.33 billion in the same quarter a year earlier.
Why did Sanofi's net income fall in Q2 FY2026?
Sanofi's net income attributable to shareholders was $398.91 million in Q2 FY2026, down 91.1% from $4.47 billion a year earlier. The quarter included an impairment writing off the drug candidate amlitelimab, and the year-earlier quarter included the gain on the sale of the Opella consumer health business.
What were Sanofi's earnings per ADS in Q2 FY2026?
Sanofi's basic earnings per American Depositary Share were $0.17 in Q2 FY2026, against $1.84 a year earlier. Business EPS, Sanofi's non-IFRS measure that excludes impairments of acquired intangibles and discontinued operations, was $1.22 per ADS, up 34.8% in US dollar terms from $0.90.
How much did Dupixent sell in Q2 FY2026?
Dupixent, Sanofi's largest medicine, had net sales of $5.99 billion in Q2 FY2026, the quarter ended June 30, 2026, out of total Sanofi net sales of $13.49 billion.
Where can I get Sanofi (SNY) financial data in machine-readable form?
Ticker Scout publishes Sanofi's financial statements as JSON at https://tickerscout.ai/sny/financials.json, free, with no API key and no signup. The 20-F and 6-K narrative and the 6-K events digest are published as Markdown at https://tickerscout.ai/sny/narrative.md and https://tickerscout.ai/sny/events.md. Sanofi's SEC CIK is 0001121404. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Sanofi (SNY) next file with the SEC?
Sanofi (SNY) is due to file its next Form 6-K with the SEC. The projected date, October 23, 2026, has passed, which means the filing is due or overdue rather than already reported here. That date is a projection rather than a company-announced date: it is derived from Sanofi's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 6-K for Q2 FY2026, the period ended 2026-06-30, SEC accession 0001628280-26-050803.
Related companies
How this page was built
This page was built from Sanofi's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names two such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.